🏛️ Verified NIH Record • Updated 2026-08-05
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) (NCT06733935)
A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Immune-Mediated Diseases
🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Nkarta, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.
Who can join: Review the eligibility criteria below.
Location: Nkarta Investigational Site — Orange, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Nkarta Investigational Site — Orange, California
- Nkarta Investigational Site — Gainesville, Florida
- Nkarta Investigational Site — Miami, Florida
- Nkarta Investigational Site — Plantation, Florida
- Nkarta Investigational Site — Chicago, Illinois
- Nkarta Investigational Site — Fairway, Kansas
- Nkarta Investigational Site — Ann Arbor, Michigan
- Nkarta Investigational Site — Minneapolis, Minnesota
- Nkarta Investigational Site — Hackensack, New Jersey
- Nkarta Investigational Site — Summit, New Jersey
- Nkarta Investigational Site — New York, New York
- Nkarta Investigational Site — Stony Brook, New York
- Nkarta Investigational Site — Syracuse, New York
- Nkarta Investigational Site — Charlotte, North Carolina
- Nkarta Investigational Site — Dallas, Texas
- Nkarta Investigational Site — Houston, Texas
- Nkarta Investigational Site — Melbourne, Victoria
- Nkarta Investigational Site — Manati,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Systemic Sclerosis
- KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis — Palo Alto, California
- Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) — Scottsdale, Arizona
- Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial — Charleston, South Carolina
- A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis — Scottsdale, Arizona
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis — New York, New York
- Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis — Houston, Texas
Explore by condition: All Systemic Sclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.